SCHEMBL5322873

SCHEMBL5322873

CN(C(=O)OC(C)(C)C)[C@@H](Cc1ccc(Cl)cc1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.48
ADAMTS5 Q9UNA0 1/20 0.45
PPARG P37231 7/20 0.43
PPARA Q07869 7/20 0.43
NPY5R Q15761 1/20 0.40
CYP3A4 P08684 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
NFKB1 P19838 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAOB P27338 1/20 0.40
GAA P10253 1/20 0.40
MMP13 P45452 1/20 0.39
LMNA P02545 1/20 0.39
PMP22 Q01453 1/20 0.39
NLRP3 Q96P20 1/20 0.39
ITGB3 P05106 1/20 0.39
ITGA2B P08514 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5803685 1.00 ADORA1 (0.48) ADORA1ADAMTS5PPARGPPARANPY5R
SCHEMBL6557867 1.00 ADORA1 (0.48) ADORA1ADAMTS5PPARGPPARANPY5R
SCHEMBL7855989 0.89 ADORA1 (0.40) ADORA1ADAMTS5MMP13ITGB3ITGA2B
SCHEMBL25173080 0.88 PPARG (0.40) ADORA1PPARGPPARAMMP13ITGB3
SCHEMBL6661008 0.88 CTSS (0.44) ADORA1MMP13ITGB3ITGA2B
SCHEMBL4778626 0.88 CTSS (0.44) ADORA1MMP13ITGB3ITGA2B
SCHEMBL8766144 0.88 CTSS (0.44) ADORA1MMP13ITGB3ITGA2B
SCHEMBL2476924 0.87 MMP13 (0.46) ADAMTS5CYP1A2MMP13ITGB3ITGA2B
SCHEMBL1401042 0.87 MMP13 (0.46) ADAMTS5CYP1A2MMP13ITGB3ITGA2B
SCHEMBL65502 0.87 MMP13 (0.46) ADAMTS5CYP1A2MMP13ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1069109-B1 Process for production of optically active N-protected-N-methyl-phenylalanine derivative AJINOMOTO KK (JP) 2004-03-03 EP claimed
US-6342629-B1 ENANTIOMORPHS FROM REACTION OF CYCLOHEXYLAMINE OR DICYCLOHEXYLAMINE AND ISOLATION AJINOMOTO CO., INC. (JP) 2002-01-29 US claimed
EP-1069109-A1 Process for production of optically active N-protected-N-methyl-phenylalanine derivative Ajinomoto Co., Inc. (JP) 2001-01-17 EP claimed
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PEPTIDREAM INC (JP) 2026-01-15 US disclosed
US-12486302-B2 Somatostatin receptor antagonist compounds and methods of using the same CDRD VENTURES INC. (CA) 2025-12-02 US disclosed
EP-4534524-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PeptiDream Inc. (JP) 2025-04-09 EP disclosed
CN-118256591-A Cyclic peptide compound having high membrane permeability and library comprising same 中外制药株式会社 2024-06-28 CN disclosed
CN-110869544-B Cyclic peptide compound having high membrane permeability and library comprising same 中外制药株式会社 2024-03-08 CN disclosed
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-09-07 US disclosed
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME CDRD VENTURES INC. (CA) 2022-04-14 US disclosed
US-11279732-B2 Somatostatin receptor antagonist compounds and methods of using the same CDRD VENTURES INC. (CA) 2022-03-22 US disclosed
US-6284778-B1 NEUROTROPHIC AGENT VERTEX PHARMACEUTICALS INCORPORATED 2001-09-04 US disclosed
EP-1069109-A1 Process for production of optically active N-protected-N-methyl-phenylalanine derivative Ajinomoto Co., Inc. (JP) 2001-01-17 EP disclosed
US-6172086-B1 TREATING PARKINSON*S DISEASE, ALZHIEMER*S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, MULTIPLE SCLEROSIS AND OTHER NERVOUS SYSTEM DISORDERS VERTEX PHARMACEUTICALS INCORPORATED 2001-01-09 US disclosed
JP-2000327665-A ALKYLHYDANTOIN COMPOUND MITSUBISHI CHEMICALS CORP 2000-11-28 JP disclosed
CN-1239433-A Methods and compositions for stimulating axonal growth using a compound having affinity for FKBP12 in combination with a neurotrophic factor VERTEX PHARMA (US) 1999-12-22 CN disclosed
EP-0946190-A1 METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS Vertex Pharmaceuticals Incorporated (US) 1999-10-06 EP disclosed
US-5840736-A PEPTIDES FOR NERVE GROWTH VERTEX PHARMACEUTICALS INCORPORATED (US) 1998-11-24 US disclosed
WO-1998020891-A1 METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 1998-05-22 WO disclosed
US-5543423-A USED IN MULTI-DRUG RESISTANCE CANCER THERAPY VERTEX PHARMACEUTICALS, INCORPORATED (US) 1996-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF NSUN3, BCAT1, SLC43A1 ADORA1 989/4885ADAMTS5 4456/4885PPARG 3131/4885
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS CHI3L1, CHI3L2, CHIA ADORA1 4769/4885ADAMTS5 555/4885PPARG 4776/4885
US-12486302-B2 Somatostatin receptor antagonist compounds and methods of using the same GPR119, SSTR5, SSTR2 ADORA1 335/4885ADAMTS5 485/4885PPARG 729/4885
US-11279732-B2 Somatostatin receptor antagonist compounds and methods of using the same GPR119, SSTR5, SSTR2 ADORA1 329/4885ADAMTS5 488/4885PPARG 752/4885
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME GPR119, SSTR5, SSTR2 ADORA1 335/4885ADAMTS5 485/4885PPARG 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.